Hodgson, Darren R.
Dougherty, Brian A.
Lai, Zhongwu
Fielding, Anitra
Grinsted, Lynda
Spencer, Stuart
O’Connor, Mark J.
Ho, Tony W.
Robertson, Jane D.
Lanchbury, Jerry S.
Timms, Kirsten M.
Gutin, Alexander
Orr, Maria
Jones, Helen
Gilks, Blake
Womack, Chris
Gourley, Charlie
Ledermann, Jonathan
Barrett, J. Carl
Article History
Received: 23 April 2018
Revised: 20 August 2018
Accepted: 4 September 2018
First Online: 24 October 2018
Ethics approval and consent to participate
: The institutional review boards or independent ethics committees of all investigational sites approved the protocol and all patients provided written, informed consent. The study was conducted in accordance with the Declaration of Helsinki, Good Clinical Practice and the AstraZeneca policy on bioethics.<sup>36</sup>
: D.R.H., B.A.D., Z.L., A.F., L.G., S.S., M.J.O.C., T.W.H., M.O., H.J. and J.C.B. are AstraZeneca employees and stockholders; J.D.R. and C.W. were AstraZeneca employees and stockholders at the time the study was conducted. J.S.L., K.M.T. and A.G. are Myriad Genetics Inc. employees and stockholders; C.G. has acted in an advisory role for AstraZeneca, Clovis, Roche and Nucana, received honoraria from AstraZeneca and Roche, and received research funding from AstraZeneca, Novartis and Aprea; J.L. has participated in an advisory board for AstraZeneca; B.G. declares no competing interests.
: This study was funded by AstraZeneca.